Biogen Analyst Price Targets - Benzinga

SPY754.90+0.37%QQQ686.33+0.77%BTC/USD77,578.29+1.18%DIA517.03−0.44%GLD360.64−0.28%TLT81.18−0.67%

Premium Services

Premium Services

Biogen Inc

BIIBNASDAQ

Trade with Public

Trade with Public

$250.99

1.980.8%

Last update: Nov 3, 10:45 AM

Overview News Earnings Forecast EventsPrice TargetsFinancials Sentiment Ownership Compare Options Stock Report

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell

© 2026 Benzinga | All Rights Reserved

Biogen Analyst Price Targets - Benzinga

Biogen Analyst Price Targets

Wall Street analyst price targets and consensus rating for Biogen (BIIB).

Price Target Range — 7 Quarters

Analyst Consensus — 25 Analysts

19Buy

6Hold

Consensus RatingBuy# Analysts25Avg. Consensus PT$246Upside to Avg. PT-1.9%

Rating Trend — Last 9 Months

Recent Analyst Actions

See all ratings →

Date	Firm	Analyst	Action	Rating Change	Price Target
Nov 2, 2026	Guggenheim	Yatin Suneja	PT Raise	Buy	$280→$300
Nov 2, 2026	HC Wainwright & Co.	Ananda Ghosh	PT Raise	Buy	$251→$270
Oct 29, 2026	Canaccord Genuity	Sumant Kulkarni	PT Raise	Buy	$248→$272
Oct 29, 2026	Argus Research	Jasper Hellweg	Upgrade	Hold→Buy	$280
Oct 29, 2026	RBC Capital	Brian Abrahams	PT Raise	Outperform	$256→$272
Oct 29, 2026	Morgan Stanley	Matthew Harrison	PT Raise	Equal-Weight	$231→$238
Oct 29, 2026	UBS	Michael Yee	PT Raise	Buy	$270→$300
Oct 29, 2026	TD Cowen	Phil Nadeau	PT Raise	Buy	$250→$260
Oct 29, 2026	Wedbush	Laura Chico	PT Raise	Neutral	$212→$225
Oct 29, 2026	Truist Securities	Danielle Brill	PT Raise	Buy	$235→$260
Oct 29, 2026	Baird	Brian Skorney	PT Raise	Outperform	$250→$290
Oct 29, 2026	Needham	Ami Fadia	PT Raise	Buy	$256→$290
Oct 28, 2026	Barclays	Emily Field	PT Raise	Equal-Weight	$200→$230
Oct 22, 2026	B of A Securities	Jason Zemansky	PT Raise	Neutral	$219→$244
Oct 21, 2026	TD Cowen	Phil Nadeau	PT Raise	Buy	$225→$250
Oct 20, 2026	Wells Fargo	Mohit Bansal	PT Raise	Overweight	$250→$310
Oct 12, 2026	JP Morgan	Chris Schott	Upgrade	Neutral→Overweight	$210→$300
Oct 9, 2026	UBS	Michael Yee	PT Raise	Buy	$240→$270
Oct 8, 2026	RBC Capital	Brian Abrahams	PT Cut	Outperform	$260→$256
Sep 10, 2026	HSBC	Rajesh Kumar	PT Raise	Reduce	$165→$175

Analyst Ratings News

PRO
Guggenheim Maintains Buy on Biogen, Raises Price Target to $300

Guggenheim analyst Yatin Suneja maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $280 to $300.

Benzinga Newsdesk

Regeneron Pharmaceuticals To Rally Around 11%? Here Are 10 Top Analyst Forecasts For Monday

Analysts upgraded MHK and CRWD, downgraded PFSI, cut ABOS’s target, and raised targets for NRXP, REGN and NTSK.

Avi Kapoor

PRO
HC Wainwright & Co. Maintains Buy on Biogen, Raises Price Target to $270

HC Wainwright & Co. analyst Ananda Ghosh maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $251 to $270.

Benzinga Newsdesk

Incyte To Rally More Than 23%? Here Are 10 Top Analyst Forecasts For Friday

Analysts raised targets for Cheniere and Incyte, while cutting Stryker, Roblox, Intel and Honeywell; Bright Horizons was downgraded.

Avi Kapoor

PRO
Canaccord Genuity Maintains Buy on Biogen, Raises Price Target to $272

Canaccord Genuity analyst Sumant Kulkarni maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $248 to $272.

Benzinga Newsdesk

PRO
Argus Research Upgrades Biogen to Buy, Announces $280 Price Target

Argus Research analyst Jasper Hellweg upgrades Biogen (NASDAQ:BIIB) from Hold to Buy and announces $280 price target.

Benzinga Newsdesk